Form D · Biotechnology

Ultragenyx Pharmaceutical Inc.

Novato, CA · CIK 0001515673

Offering snapshot reported Dec 31, 2012 · SEC filing

Reported sold
$75M
Offering amount: $75M
Investors reported
34
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 18, 2012
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 31, 2012Initial$75,000,005No comparison34SEC filing
Jul 30, 2012Initial$15,100,000No comparison6SEC filing
Jun 23, 2011Initial$18,664,443No comparison8SEC filing
Mar 16, 2011Initial$133No comparison3SEC filing

Offering details

Securities
Equity
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$938K
Finders' fees
$0
Form D file number
021-189181

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
COWEN AND COMPANY7616

Source: Form D, filed Dec 31, 2012. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Bill Aliski Director
William Aliski Director
Ben Auspitz Director
John Ditton Executive
Steven Jungles Executive
Emil D. Kakkis Director, Executive
Thomas Kassberg Executive
John Klock Director
Cordelia Leonard Executive
Eran Nadav Director
Shalini Sharp Executive
Jenny Soriano Director
Vimal Srivastava Executive
Marten Steen Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
60 Leveroni Court
Novato, CA, 94949